Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial.

Author(s): Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C

Affiliation(s): Departments of 1Global Health, 2Medicine, 3Laboratory Medicine, and 4Epidemiology, University of Washington, and the 5Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle; 6Asociacion Civil Impacta Salud y Educacion, Lima, Peru.

Publication date & source: 2008-10-17, J Infect Dis., [Epub ahead of print]

Publication type:

A randomized cross-over trial of herpes simplex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20 Peruvian women coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) who were not on antiretroviral therapy. Plasma samples (obtained weekly) and endocervical swab specimens (obtained thrice weekly) were collected for HIV-1 RNA polymerase chain reaction. Plasma HIV-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (-0.26 log(10) copies/mL, a 45% decrease [[Formula: see text]]), as was cervical HIV-1 level (-0.35 log(10) copies/swab, a 55% decrease [[Formula: see text]]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression. Trial registration. @nbsp; ClinicalTrials.gov identifier: NCT00465205 .